Form 4: Baker Bros. Directors Boost Bicycle Therapeutics Stake

Baker Bros. Advisors LP and affiliated entities reported the acquisition of restricted share units and share options in Bicycle Therapeutics PLC for director Felix J. Baker.

Summary

• Felix J. Baker, a director of Bicycle Therapeutics PLC and managing member of Baker Bros. Advisors (GP) LLC, was granted 19,000 Restricted Share Units (RSUs) and 38,000 Share Options on January 2, 2026.
• The RSUs and Share Options were granted under the Issuer's 2020 Equity Incentive Plan.
• The RSUs are payable in American Depositary Shares (ADS) or Ordinary Shares at the Issuer's option, with a price of $0 per unit.
• The Share Options have a strike price of $7.08 and are exercisable into ADS or Ordinary Shares at the Issuer's option.
• Both the RSUs and Share Options vest in four equal quarterly installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026, contingent on Felix J. Baker's continuous service on the Board.
• Baker Bros. Advisors LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, Felix J. Baker, and Julian C. Baker are all reporting persons, deemed directors by deputization and 10% owners.
• Julian C. Baker and Felix J. Baker hold an indirect pecuniary interest in these securities through their ownership interests in 667, L.P. and Baker Brothers Life Sciences, L.P. (the 'Funds').
• Baker Bros. Advisors LP serves as the investment adviser to the Funds and has complete discretion over the investment and voting power of the securities held by the Funds.
• Following these transactions, the indirect beneficial ownership of American Depositary Shares for the Funds is reported as 937,483 and 10,018,674, respectively, and 38,000 Share Options for each Fund.

Sentiment

Score: 7

Explanation: The filing indicates a positive alignment of interests between a key director/major shareholder group and the company's long-term performance through equity compensation. While not a direct cash investment, it signals continued commitment and confidence.

Positives

• The grant of equity compensation to director Felix J. Baker aligns his interests and those of the Baker Bros. affiliated funds with the long-term performance of Bicycle Therapeutics PLC.
• The vesting schedule, tied to continuous board service, encourages sustained commitment from a significant shareholder representative.
• The transaction reflects ongoing engagement and investment by a major institutional investor group in the company's future.

Negatives

• The compensation is equity-based, meaning its value is directly tied to the future stock performance of Bicycle Therapeutics PLC, introducing market risk.
• There is no direct cash investment by the reporting persons in these specific transactions, as the RSUs and options were granted at a price of $0.

Risks

• The vesting of RSUs and Share Options is contingent upon Felix J. Baker's continuous service on the board of directors, meaning unvested portions could be forfeited if service ceases.
• The value of the acquired securities (RSUs and Share Options) is subject to the market price fluctuations of Bicycle Therapeutics PLC's American Depositary Shares.
• The exercise price of the Share Options ($7.08) means that the options will only have intrinsic value if the share price exceeds this amount at the time of exercise.

Future Outlook

The grants of equity compensation to a key director and significant shareholder group indicate a long-term perspective and continued commitment to the company's success, with vesting schedules extending through the end of 2026 and option expiration in 2036.

Industry Context

Equity-based compensation, such as Restricted Share Units and Share Options, is a common practice in the biotechnology industry to attract and retain key talent, including directors, and to align their incentives with long-term shareholder value creation. This filing reflects a standard approach to director compensation within the sector.

Comparison to Industry Standards

• The use of RSUs and Share Options for director compensation is a standard practice across the biotechnology and pharmaceutical industries, similar to compensation structures seen at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, where equity incentives are a significant component of executive and director pay.
• The vesting schedule tied to continuous service is typical for such grants, ensuring ongoing commitment from the director.
• The indirect beneficial ownership structure through investment funds, where the director has a pecuniary interest, is also common for representatives of large institutional investors serving on boards.

Corporate Governance

Related Party Transactions

• The grants of RSUs and Share Options to Felix J. Baker, a director of Bicycle Therapeutics PLC, are considered related party transactions given his role and his affiliation with Baker Bros. Advisors LP, which advises the 10% owner funds (667, L.P. and Baker Brothers Life Sciences, L.P.).
• Julian C. Baker and Felix J. Baker have an indirect pecuniary interest in these securities through their ownership interests in the Funds and their general partners.

Stakeholder Impact

• Shareholders: The equity grants align the interests of a significant director and major institutional investor group with long-term shareholder value, potentially fostering more stable and strategic decision-making.
• Employees: While not directly impacting employees, the use of an equity incentive plan for directors sets a precedent for performance-based compensation within the company's governance structure.
• Board of Directors: The compensation structure incentivizes Felix J. Baker's continued service and engagement on the Board.

Next Steps

• The RSUs and Share Options will vest in four equal quarterly installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026, subject to Felix J. Baker's continuous board service.
• Previously granted RSUs will continue to vest, with 8,000 remaining to vest in two equal annual installments beginning on April 18, 2026.

Key Dates

Recommendation

This Form 4 reports routine equity compensation for a director, which aligns insider interests with long-term shareholder value. It does not present new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Bicycle Therapeutics, BCYC, SEC Form 4, Insider Transaction, Director Compensation, Equity Incentive Plan, Restricted Share Units, Stock Options, Baker Bros. Advisors, Biotechnology